SCHEMBL6033692

SCHEMBL6033692

NC(Cc1ccccc1)CS(=O)(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.59
ANPEP P15144 2/20 0.52
ALPI P09923 1/20 0.50
PKM P14618 1/20 0.50
PTGS1 P23219 1/20 0.50
XIAP P98170 1/20 0.50
SLC7A5 Q01650 1/20 0.50
MMP2 P08253 3/20 0.47
LAP3 P28838 3/20 0.47
SLC1A3 P43003 1/20 0.46
SLC1A2 P43004 1/20 0.46
SLC1A1 P43005 1/20 0.46
SLC6A2 P23975 2/20 0.45
TAAR1 Q96RJ0 2/20 0.45
MAOA P21397 1/20 0.45
SLC6A4 P31645 1/20 0.45
SLC6A3 Q01959 1/20 0.45
SIGMAR1 Q99720 1/20 0.45
CYP2A6 P11509 1/20 0.45
ADORA2A P29274 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8527002 1.00 EPHX1 (0.59) EPHX1ANPEPALPIPKMPTGS1
SCHEMBL27712365 1.00 EPHX1 (0.59) EPHX1ANPEPALPIPKMPTGS1
Hydrochloric Acid SCHEMBL29410716 0.98 EPHX1 (0.57) EPHX1ANPEPALPIPKMPTGS1
SCHEMBL8748122 0.83 TAAR1 (0.50) SLC7A5SLC6A2TAAR1
SCHEMBL18167808 0.82 EPHX1 (0.61) EPHX1ANPEPALPIPKMPTGS1
SCHEMBL18167806 0.82 EPHX1 (0.61) EPHX1ANPEPALPIPKMPTGS1
SCHEMBL27700316 0.81 ANPEP (0.50) EPHX1ANPEP
SCHEMBL27720875 0.81 EPHX1 (0.55) EPHX1ANPEPALPIPKMPTGS1
SCHEMBL352772 0.81 EPHX1 (0.55) EPHX1ANPEPALPIPKMPTGS1
SCHEMBL27700318 0.81 EPHX1 (0.55) EPHX1ANPEPALPIPKMPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116875980-A Copper-reducing additive for HDI board and copper-reducing process 上海天承化学有限公司 2023-10-13 CN claimed
CN-114605976-A Polysulfonic acid silane composite graphene oxide plugging agent and oil-based drilling fluid 西南石油大学 2022-06-10 CN claimed
EP-0467856-B1 Aminoalkanesulfonic acid derivatives and pharmaceutical compositions for use in preventing or treating heart diseases NIPPON ZOKI PHARMACEUTICAL CO (JP) 1997-03-19 EP claimed
EP-0467856-A2 Aminoalkanesulfonic acid derivatives and pharmaceutical compositions for use in preventing or treating heart diseases NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) 1992-01-22 EP claimed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 US disclosed
CN-116875980-A Copper-reducing additive for HDI board and copper-reducing process 上海天承化学有限公司 2023-10-13 CN disclosed
CN-116234802-A Quinoline CGAS antagonist compounds 免疫传感器治疗股份有限公司 2023-06-06 CN disclosed
CN-114605976-A Polysulfonic acid silane composite graphene oxide plugging agent and oil-based drilling fluid 西南石油大学 2022-06-10 CN disclosed
CN-101851182-B Salt-free preparation method for substituted taurine UNIV BEIJING CHEMICAL 2013-07-17 CN disclosed
CN-101337914-B Preparation method of taurine and substituted taurine UNIV BEIJING CHEMICAL 2012-04-04 CN disclosed
CN-101255126-B Preparation of taurine and derivatives thereof UNIV BEIJING 2010-12-01 CN disclosed
CN-101148427-B Method for preparing substituted taurine UNIV BEIJING 2010-10-27 CN disclosed
US-20050038000-A1 Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2005-02-17 US disclosed
WO-2005000406-A2 TREATMENT OF AMYLOID- AND EPILEPTOGENESIS-ASSOCIATED DISEASES NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2005-01-06 WO disclosed
CN-1369496-A Use of compound with structure similar to L-phenylalanine as medicine to treat skin diseases LU XIAODE (CN) 2002-09-18 CN disclosed
EP-0460679-B1 Endothelin antagonistic peptide derivatives BANYU PHARMA CO LTD (JP) 1998-10-28 EP disclosed
US-5691315-A CARDIOVASCULAR DISORDERS; VASODILATOR; BRONCHODILATOR BANYU PHARMACEUTICAL CO., LTD. (JP) 1997-11-25 US disclosed
US-5470833-A Vasodilators, bronchodilators BANYU PHARMACEUTICAL CO., LTD. (JP) 1995-11-28 US disclosed
US-5444152-A Vasolidator or bronchodilator BANYU PHARMACEUTICAL CO., LTD. (JP) 1995-08-22 US disclosed
EP-0460679-A2 Endothelin antagonistic peptide derivatives Banyu Pharmaceutical Co., Ltd. (JP) 1991-12-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873291-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS EPHX1 3226/4885ANPEP 1189/4885ALPI 2273/4885
US-20050038000-A1 Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases APP, PSEN1, PSEN2 EPHX1 148/4885ANPEP 640/4885ALPI 1651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.